Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Indivior Temettü

Temettü kriter kontrolleri 0/6

Indivior şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

Ödeme oranı

Sektör ortalama getirisi	2.3%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	UK£0.476
Hisse başına kazanç	-UK£1.09
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Sep 24

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Aug 09

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

May 29

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

May 03

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: INDV şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: INDV şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Indivior Piyasaya Karşı Temettü Getirisi

INDV temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (INDV)	0%
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.6%
Sektör Ortalaması (Pharmaceuticals)	2.3%
Analist tahmini (INDV) (3 yıla kadar)	0%

Önemli Temettü: INDV şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, INDV şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: INDV UK piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: INDV herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Indivior Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Indivior PLC Announces Retirement of Graham Hetherington as Chair and from the Board

Positive Sentiment Still Eludes Indivior PLC (LON:INDV) Following 26% Share Price Slump

Indivior PLC Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Moderate to Severe Cannabis Use Disorder

Addex Therapeutics Ltd and Indivior PLC Selects Clinical Candidates from Gabab Positive Allosteric Modulator Research Collaboration

Indivior PLC's (LON:INDV) Shares Leap 37% Yet They're Still Not Telling The Full Story

Pomerantz Law Firm Announces the Filing of a Class Action Against Indivior PLC and Certain Officers

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,649,017 shares, for $100 million.

Consensus EPS estimates increase by 44%

Consensus EPS estimates fall by 37%

Indivior PLC Revises Financial Guidance for the Fiscal Year 2024

Indivior PLC Provides Revenue Guidance for the Second Quarter of 2024

Indivior PLC(LSE:INDV) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Indivior PLC Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (Ovee 2.7Mg) and In Naloxone (4 Mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression on Respiratory Depression

Indivior PLC Announces Dosing of First Subject with Indv-2000 in A Phase 2 Study Assessing the Safety and Efficacy of Indv-2000 in Individuals with Opioid Use Disorder

Indivior PLC's (LON:INDV) Shares Not Telling The Full Story

Indivior plc Reaffirms Revenue Guidance for the Year 2024

Indivior PLC Announces Board Committee Changes

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Chief Human Resources Officer recently sold UK£1.8m worth of stock

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

New major risk - Financial position

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings: Revenues in line with analyst expectations

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior (LON:INDV) Seems To Use Debt Quite Sensibly

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Investor sentiment deteriorated over the past week

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022